Overcoming Barriers to Treatment in
Strategies to Manage Adverse Events
Associated with Immunotherapies
A continuing medical education activity sponsored by NAMCP and AAMCN.
New Horizons in the Treatment of
Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC):
How Immunotherapies Are Changing the Treatment Paradigm
This is Part III of the series focusing on Barriers to Treatment in
This activity is an archive from the webinar held September 13,
2017. If you participated
in the live webinar, you are not eligible for credits for this
This activity is valid from November 1, 2017 to
November 30, 2018
Instructions for CME/CNE: Complete the pre test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. If you close your internet browser without
completing the post test, you will have ONE more opportunity to
complete. A score of 70% must be achieved on the post test to
receive continuing education credits. If you do not pass the post
test after two attempts, you will not be eligible to try again. Once
you complete the evaluation form and score 70% or higher on your
post test, you will automatically be given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
an educational grant from
Merck Sharp & Dohme Corp
Head and neck squamous cell carcinoma (HNSCC) represents a
heterogeneous group of tumors that originate in the lip/oral cavity,
hypopharynx, oropharynx, nasopharynx, and larynx. An estimated
48,330 new cases are diagnosed annually in the United States, and
9,570 people die of the disease. HNSCC historically has been
associated with tobacco and alcohol use; however, during the past
decade, infection with high-risk human papillomavirus (HPV) has been
implicated in the pathogenesis of a growing subset of HNSCCs.
Despite advances and innovations in multimodality treatment and a
better understanding of head and neck carcinogenesis, survival rates
of locally metastatic HNSCC have not substantially improved, and the
prognosis for recurrent/metastatic disease remains poor. Fortunately
for patients with metastatic HNSCC, new immunotherapeutic options,
which have shown improved efficacy and safety, have recently become
available to give clinicians and managed care professionals more
options when managing a population of metastatic HNSCC patients.
This webinar will be part three of a four-part webinar series, and
it will look closely at overcoming barriers to treatment in
metastatic HNSCC, with a close look and managing immune-related
Upon Completion of this
activity, participants will be able to:
Discuss challenges and barriers that
healthcare professionals face when managing metastatic HNSCC
Identify adverse events commonly
associated with immunotherapeutic agents used in the treatment
of metastatic HNSCC
Discuss strategies to mitigate side
effects related to treatment with immunotherapeutic agents in
patients with metastatic HNSCC
Assess the informational needs of
patients and families/caregivers regarding their treatment plan
and identify methods to counsel them
Review how treatment strategies can
be affected by adverse events based on patient’s individualized
||Robert L. Ferris, MD,
Professor and Chief, Division of Head and Neck Surgery,
Departments of Otolaryngology, Radiation Oncology, and
Immunology; Co-leader, Cancer Immunology Program
UPMC Hillman Cancer Center
serves as an advisor for Amgen, AstraZeneca/MedImmune,
Bristol-Myers Squibb, EMD Serono, PPD (Benetic), Lilly,
Merck, and Pfizer. He has received and or receives
research support from AstraZeneca/MedImmune,
Bristol-Myers Squibb, VentiRx Pharmaceuticals. Dr.
Ferris also received clinical trial funding from
AstraZeneca/MedImmune, Bristol-Myers Squibb, and Merck.
His presentation has been peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA PRA
Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by
the American Board of Managed Care Nursing for 1.0 contact hours
toward CMCN recertification requirements.
supported by an educational grant from
Merck Sharp & Dohme Corp
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue